LONGEVERON INC-A
LGVNNASDAQTrading Snapshot
- Day Range
- $2.68 – $2.77
- 52-Week Range
- $2.30 – $12.30
- Volume
- $2.15B
- Avg Volume
- $1.93B
- Shares Outstanding
- 3.0M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $287,000
- P/E Ratio
- -0.3
- P/S Ratio
- 7.2x
- EPS (TTM)
- $-7.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +54.0%
Why Investors Own LGVN
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LONGEVERON INC-A
LGVN
StockOtter · stockotter.spaceAbout LONGEVERON INC-A
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
Longeveron Announces 1-for-10 Reverse Stock Split
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) --
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript